Drugs / Pneumococcal Conjugate Vaccine formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04398706 | May 2020 → Aug 2023 | chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal Conjugate Vaccine formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04398706 ↗ |
| Modality | Vaccine | “Pneumococcal Conjugate Vaccine formulation 2” NCT04398706 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular” NCT04398706 ↗ |